JP5917148B2 - 認知機能を改善するための方法および組成物 - Google Patents

認知機能を改善するための方法および組成物 Download PDF

Info

Publication number
JP5917148B2
JP5917148B2 JP2011532085A JP2011532085A JP5917148B2 JP 5917148 B2 JP5917148 B2 JP 5917148B2 JP 2011532085 A JP2011532085 A JP 2011532085A JP 2011532085 A JP2011532085 A JP 2011532085A JP 5917148 B2 JP5917148 B2 JP 5917148B2
Authority
JP
Japan
Prior art keywords
oxo
methyl
hydrogen
alkyl
butanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011532085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505883A (ja
JP2012505883A5 (enExample
Inventor
ミカエラ ギャラガー，
ミカエラ ギャラガー，
レベッカ ハーバーマン，
レベッカ ハーバーマン，
ミン テン コー，
ミン テン コー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2012505883A publication Critical patent/JP2012505883A/ja
Publication of JP2012505883A5 publication Critical patent/JP2012505883A5/ja
Application granted granted Critical
Publication of JP5917148B2 publication Critical patent/JP5917148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011532085A 2008-10-16 2009-10-16 認知機能を改善するための方法および組成物 Active JP5917148B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10584708P 2008-10-16 2008-10-16
US61/105,847 2008-10-16
US15263109P 2009-02-13 2009-02-13
US61/152,631 2009-02-13
US17553609P 2009-05-05 2009-05-05
US61/175,536 2009-05-05
PCT/US2009/005647 WO2010044878A1 (en) 2008-10-16 2009-10-16 Methods and compositions for improving cognitive function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014129145A Division JP2014169339A (ja) 2008-10-16 2014-06-24 認知機能を改善するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2012505883A JP2012505883A (ja) 2012-03-08
JP2012505883A5 JP2012505883A5 (enExample) 2012-11-29
JP5917148B2 true JP5917148B2 (ja) 2016-05-11

Family

ID=41403972

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011532085A Active JP5917148B2 (ja) 2008-10-16 2009-10-16 認知機能を改善するための方法および組成物
JP2014129145A Withdrawn JP2014169339A (ja) 2008-10-16 2014-06-24 認知機能を改善するための方法および組成物
JP2016103917A Active JP6271641B2 (ja) 2008-10-16 2016-05-25 認知機能を改善するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014129145A Withdrawn JP2014169339A (ja) 2008-10-16 2014-06-24 認知機能を改善するための方法および組成物
JP2016103917A Active JP6271641B2 (ja) 2008-10-16 2016-05-25 認知機能を改善するための方法および組成物

Country Status (12)

Country Link
US (5) US20100099735A1 (enExample)
EP (2) EP3260118B1 (enExample)
JP (3) JP5917148B2 (enExample)
CN (2) CN102227217A (enExample)
AU (1) AU2009303834B2 (enExample)
BR (1) BRPI0920342A2 (enExample)
CA (1) CA2740610C (enExample)
DK (2) DK3260118T3 (enExample)
EA (1) EA033130B1 (enExample)
ES (2) ES2637497T3 (enExample)
HK (1) HK1245099A1 (enExample)
WO (1) WO2010044878A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009303834B2 (en) 2008-10-16 2016-08-11 The Johns Hopkins University Methods and compositions for improving cognitive function
CN109662961A (zh) * 2011-02-09 2019-04-23 约翰斯霍普金斯大学 用于改善认知功能的方法和组合物
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2968237A4 (en) * 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
US20160030391A1 (en) * 2013-03-15 2016-02-04 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
BR112017025031B1 (pt) * 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
MA50634A (fr) * 2015-05-22 2021-04-28 Agenebio Inc Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam
CN109069480A (zh) 2015-12-30 2018-12-21 阿达玛斯医药公司 用于治疗与癫痫相关的病症的方法和组合物
EP3458049B1 (en) * 2016-05-20 2025-03-05 Institut Pasteur Levetiracetam, brivaracetam or selectracetam for use in treating sepsis induced acute brain dysfunction
US10370561B2 (en) 2016-06-28 2019-08-06 Prc-Desoto International, Inc. Urethane/urea-containing bis(alkenyl) ethers, prepolymers prepared using urethane/urea-containing bis(alkenyl) ethers, and uses thereof
US11098222B2 (en) 2018-07-03 2021-08-24 Prc-Desoto International, Inc. Sprayable polythioether coatings and sealants
CN109892247B (zh) * 2019-04-19 2023-08-18 桂林医学院 一种猫参与的检测大鼠认知功能的实验装置
US20220354807A1 (en) * 2019-09-30 2022-11-10 Xiamen University Use of valeric acid derivative in treatment of down's syndrome
IL299754A (en) * 2020-07-10 2023-03-01 Agenebio Inc Combinations of gaba alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
JP2024508052A (ja) * 2021-02-26 2024-02-21 シンデシ セラピューティクス ソシエテ アノニム 認知障害の治療のための化合物
IL319072A (en) 2022-08-19 2025-04-01 Agenebio Inc History of Benzazepine, Compositions and Methods for Treating Cognitive Impairment

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
IT1045043B (it) * 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
IT1075280B (it) * 1977-02-11 1985-04-22 Isf Spa Procedimento per la preparazione di derivati pirrolidinici
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
DE2960194D1 (en) * 1978-05-08 1981-04-16 Ucb Sa Lactam-n-acetic acids, their amides, process for their preparation and therapeutic compositions containing them
US4654370A (en) 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4372960A (en) * 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
FR2515179A1 (fr) * 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
IL67623A (en) 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
JPS6222785A (ja) * 1985-07-23 1987-01-30 Sanwa Kagaku Kenkyusho:Kk 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
IT1190133B (it) * 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3709230A1 (de) * 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
JPS6422883A (en) * 1987-07-17 1989-01-25 Sanwa Kagaku Kenkyusho Co 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
EP0300111B1 (en) * 1987-07-22 1991-10-16 Farvalsa AG A moisture stable solid valproic acid formulation and a method of preparing the same
AU625157B2 (en) 1989-01-17 1992-07-02 F. Hoffmann-La Roche Ag Cyclohexaneacetamide derivatives
FR2643556B1 (fr) 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
CA2067614C (en) * 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
US5439930A (en) * 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
US5440023A (en) 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5516759A (en) 1994-12-08 1996-05-14 Tap Holdings Inc. LHRH antagonists having lactam groups at the N-terminus
IT1285801B1 (it) 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
US6131106A (en) 1998-01-30 2000-10-10 Sun Microsystems Inc System and method for floating-point computation for numbers in delimited floating point representation
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
MXPA02005275A (es) 1999-12-01 2003-02-17 Ucb Sa Derivado de pirrolidinacetamida solo en combinacion para el tratamiento de trastornos del sistema nervioso central.
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
DE60138733D1 (de) * 2000-12-28 2009-06-25 Hamilton Pharmaceuticals Inc Arzneimittel zur behandlung und vermeidung neurogener schmerzen
US6610326B2 (en) 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
ES2311537T3 (es) * 2001-08-22 2009-02-16 Hamilton Pharmaceuticals, Inc. Utilizacion de nefiracetam en el tratamiento de la neurodegeneracion postquemica.
EP1435944B1 (en) 2001-10-16 2009-09-30 Memory Pharmaceutical Corporation 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
WO2004051222A2 (en) * 2002-12-03 2004-06-17 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
ITMI20030573A1 (it) * 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
MXPA06006026A (es) 2003-12-02 2006-08-23 Ucb Sa Derivados de imidazol, procesos para prepararlos y sus usos.
EP1740573A1 (en) 2004-04-22 2007-01-10 Eli Lilly And Company Amides as bace inhibitors
BRPI0511956A (pt) 2004-06-11 2008-01-22 Ucb Sa processo para a preparação dos compostos, e, intermediários de sìntese
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
AU2005325930B2 (en) * 2005-01-27 2012-01-19 Alembic Limited Extended release formulation of Levetiracetam
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
US8216611B2 (en) * 2005-03-30 2012-07-10 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
ES2441178T3 (es) 2005-06-01 2014-02-03 Ucb Pharma, S.A. Derivados de 2-oxo-1-pirrolidina, procedimientos para prepararlos y el uso terapéutico de los mismos sobre el sistema nervioso central
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
EP1963325A2 (en) 2005-12-07 2008-09-03 UCB Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007104035A1 (en) 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
AU2007346591A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
WO2008132142A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
WO2009038412A2 (en) 2007-09-21 2009-03-26 Lg Life Sciences, Ltd. Beta-secretase inhibiting compounds
US20090176740A1 (en) 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
MX2010009222A (es) * 2008-03-03 2010-09-28 Ucb Pharma Sa Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
JP2010024156A (ja) 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
AU2009303834B2 (en) 2008-10-16 2016-08-11 The Johns Hopkins University Methods and compositions for improving cognitive function
US9125898B2 (en) * 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
BRPI0921313A2 (pt) 2008-11-18 2015-12-29 Ucb Pharma Sa composição farmaucêutica
PL2391351T3 (pl) 2009-01-29 2015-02-27 Ucb Pharma Sa Kompozycje farmaceutyczne zawierające pochodne 2-okso-1-pirolidyny
EP2393483B1 (en) 2009-02-09 2017-06-28 UCB Biopharma SPRL Pharmaceutical compositions comprising brivaracetam
EP2461808A2 (en) 2009-08-07 2012-06-13 UCB Pharma S.A. Methods for enhancing the cognitive function
BR112017025031B1 (pt) * 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam

Also Published As

Publication number Publication date
CA2740610A1 (en) 2010-04-22
EP2346500A1 (en) 2011-07-27
JP6271641B2 (ja) 2018-01-31
HK1248543A1 (en) 2018-10-19
JP2012505883A (ja) 2012-03-08
EP2346500B1 (en) 2017-05-17
HK1245099A1 (zh) 2018-08-24
ES2865504T3 (es) 2021-10-15
AU2009303834A1 (en) 2010-04-22
DK3260118T3 (da) 2021-04-19
DK2346500T3 (en) 2017-07-17
EA033130B1 (ru) 2019-08-30
JP2014169339A (ja) 2014-09-18
ES2637497T3 (es) 2017-10-13
US20100099735A1 (en) 2010-04-22
AU2009303834B2 (en) 2016-08-11
US8604075B2 (en) 2013-12-10
WO2010044878A1 (en) 2010-04-22
CN102227217A (zh) 2011-10-26
JP2016147915A (ja) 2016-08-18
BRPI0920342A2 (pt) 2020-06-23
CA2740610C (en) 2020-01-07
CN107243007A (zh) 2017-10-13
US20240293363A1 (en) 2024-09-05
EA201170571A1 (ru) 2011-12-30
EP3260118B1 (en) 2021-03-24
EP3260118A1 (en) 2017-12-27
US20220218665A1 (en) 2022-07-14
US20150094352A1 (en) 2015-04-02
US20120046336A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
JP6271641B2 (ja) 認知機能を改善するための方法および組成物
US20230277501A1 (en) Methods and compositions for improving cognitive function
US20230033195A1 (en) Methods and compositions for improving cognitive function
US20160030391A1 (en) Methods and compositions for improving cognitive function
HK1248543B (en) Methods and compositions for improving cognitive function
HK1160005A (en) Methods and compositions for improving cognitive function
EA044839B1 (ru) Способы и композиции для улучшения когнитивной функции
HK1160007B (en) Methods and compositions for improving cognitive function
HK1160007A (en) Methods and compositions for improving cognitive function
RU2792010C2 (ru) Способы и композиции для улучшения когнитивных функций
HK1261244A1 (en) Levetiracetam for improving cognitive function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140320

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140422

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160406

R150 Certificate of patent or registration of utility model

Ref document number: 5917148

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250